What does LITHI - PHARMA do?

LITHI - PHARMA is a fitness centre in Gistel. Public Limited, started on 6 January 1993, 2 establishments.

What is the address of LITHI - PHARMA?

The registered office of LITHI - PHARMA is located at Zomerloosstraat 33 box A, 8470 Gistel.

Is LITHI - PHARMA still active?

Yes. According to the CBE (29 October 2026) LITHI - PHARMA is active, legal situation “Normale toestand”, started on 6 January 1993.

Is LITHI - PHARMA registered on Peppol?

Yes, LITHI - PHARMA is registered on the Peppol network with ID 0208:0449135041.

What is the enterprise number of LITHI - PHARMA?

The enterprise number of LITHI - PHARMA is BE0449135041.

When was LITHI - PHARMA founded?

LITHI - PHARMA was founded on 6 January 1993.

Who are the directors of LITHI - PHARMA?

According to the 2025 annual accounts, the directors of LITHI - PHARMA are: Thierry BAETSLE, Lien Matton.

Is LITHI - PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 6 January 1993; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 2 establishments in the CBE.

How much profit did LITHI - PHARMA make in 2025?

LITHI - PHARMA recorded a loss after taxes of € 223,557 in financial year 2025.

What is the revenue of LITHI - PHARMA?

As a small company, LITHI - PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 149,752.

LITHI - PHARMA (Public Limited) - Gistel - BE0449135041

Dossier LITHI - PHARMA, printed on 29 October 2026 from databakkes.be/en/0449135041/lithi-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 32 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

LITHI - PHARMA from Gistel, company number BE0449135041, closed financial year 2025 with a result of € -223,557 after tax. For that financial year LITHI - PHARMA recorded a gross margin of € 149,752 and equity of € 553,324. Compared with financial year 2024, the result moved from € -18,359 to € -223,557. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on December 29, 2025.

What it is worth Healthy

€ 553,324

▼ 29% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -223,557

▼ 1118 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 24,844

▲ € 22,518 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 353,324.

People and assets in 2025

Vehicles and equipment

€ 3,361

▼ 61% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 11 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 633,782

▼ 7% vs 2024

€ 56,077 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.

Owed to suppliers

€ 70,156

▲ € 68,640 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 10,043

▲ 114% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 124,145 Gross margin 2022: € 124,145 First fiscal year in the series	€ 204,719 Gross margin 2023: € 204,719 ▲ 65% vs 2022 (€ 124,145) Favourable step	€ 41,181 Gross margin 2024: € 41,181 ▼ 80% vs 2023 (€ 204,719) Unfavourable step	€ 149,752 Gross margin 2025: € 149,752 ▲ 264% vs 2024 (€ 41,181) Favourable step	▲ 264%
Profit after taxes	€ 28,249 Profit after taxes 2022: € 28,249 First fiscal year in the series	€ 119,769 Profit after taxes 2023: € 119,769 ▲ € 91,520 vs 2022 (€ 28,249) Favourable step	€ -18,359 Profit after taxes 2024: € -18,359 ▼ € 138,128 vs 2023 (€ 119,769) Unfavourable step	€ -223,557 Profit after taxes 2025: € -223,557 ▼ € 205,197 vs 2024 (€ -18,359) Unfavourable step	▼ € 205,197
Equity	€ 675,471 Equity 2022: € 675,471 First fiscal year in the series	€ 795,240 Equity 2023: € 795,240 ▲ 18% vs 2022 (€ 675,471) Favourable step	€ 776,881 Equity 2024: € 776,881 ▼ 2% vs 2023 (€ 795,240) Unfavourable step	€ 553,324 Equity 2025: € 553,324 ▼ 29% vs 2024 (€ 776,881) Unfavourable step	▼ 29%
Total debts	€ 1,485,936 Total debts 2022: € 1,485,936 First fiscal year in the series	€ 1,291,281 Total debts 2023: € 1,291,281 ▼ 13% vs 2022 (€ 1,485,936) Favourable step	€ 1,029,929 Total debts 2024: € 1,029,929 ▼ 20% vs 2023 (€ 1,291,281) Favourable step	€ 923,223 Total debts 2025: € 923,223 ▼ 10% vs 2024 (€ 1,029,929) Favourable step	▼ 10%
Cash	€ 8,349 Cash 2022: € 8,349 First fiscal year in the series	€ 23,438 Cash 2023: € 23,438 ▲ 181% vs 2022 (€ 8,349) Favourable step	€ 2,326 Cash 2024: € 2,326 ▼ 90% vs 2023 (€ 23,438) Unfavourable step	€ 24,844 Cash 2025: € 24,844 ▲ € 22,518 vs 2024 (€ 2,326) Favourable step	▲ € 22,518
Land & buildings	€ 1,346,871 Land & buildings 2022: € 1,346,871 First fiscal year in the series	€ 1,150,735 Land & buildings 2023: € 1,150,735 ▼ 15% vs 2022 (€ 1,346,871) Unchanged	€ 1,123,183 Land & buildings 2024: € 1,123,183 ▼ 2% vs 2023 (€ 1,150,735) Unchanged	€ 1,165,672 Land & buildings 2025: € 1,165,672 ▲ 4% vs 2024 (€ 1,123,183) Unchanged	▲ 4%
Retained profit	€ 475,471 Retained profit 2022: € 475,471 First fiscal year in the series	€ 595,240 Retained profit 2023: € 595,240 ▲ 25% vs 2022 (€ 475,471) Favourable step	€ 576,881 Retained profit 2024: € 576,881 ▼ 3% vs 2023 (€ 595,240) Unfavourable step	€ 353,324 Retained profit 2025: € 353,324 ▼ 39% vs 2024 (€ 576,881) Unfavourable step	▼ 39%
Bank debt	€ 950,265 Bank debt 2022: € 950,265 First fiscal year in the series	€ 891,181 Bank debt 2023: € 891,181 ▼ 6% vs 2022 (€ 950,265) Favourable step	€ 684,904 Bank debt 2024: € 684,904 ▼ 23% vs 2023 (€ 891,181) Favourable step	€ 633,782 Bank debt 2025: € 633,782 ▼ 7% vs 2024 (€ 684,904) Favourable step	▼ 7%
Balance sheet total	€ 2,324,531 Balance sheet total 2022: € 2,324,531 First fiscal year in the series	€ 2,262,080 Balance sheet total 2023: € 2,262,080 ▼ 3% vs 2022 (€ 2,324,531) Unchanged	€ 1,974,369 Balance sheet total 2024: € 1,974,369 ▼ 13% vs 2023 (€ 2,262,080) Unchanged	€ 1,610,593 Balance sheet total 2025: € 1,610,593 ▼ 18% vs 2024 (€ 1,974,369) Unchanged	▼ 18%

Key figures of LITHI - PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to LITHI - PHARMA?

What happened at LITHI - PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2027 Thierry BAETSLE stepped down as director. NBB
2027 Lien Matton stepped down as director. NBB
Dec 29, 2025 New annual accounts for financial year 2025: loss of € 223,557. Source: NBB ↗
2021 Thierry BAETSLE became a director. NBB
2021 Lien Matton became a director. NBB
Feb 1, 2014 New establishment in Gistel. KBO
Jan 25, 1993 New establishment in Gistel. KBO
Jan 6, 1993 Start of the company according to the CBE. KBO

In short

From € 28,249 profit in 2022 to € 223,557 loss in 2025.

Best year ever: 2023, with € 119,769 profit.

Original PDFs at the National Bank ↗

Management

LITHI - PHARMA

Bioclin 49.8%

It owns 49.8% of Bioclin itself.

Directors

According to the 2025 annual accounts

Thierry BAETSLE

Managing director

since 2021 · until 2027

Lien Matton

Director

Also active at: BIOCLIN

since 2021 · until 2027

Establishments

Establishment units

Physical locations of this company

Registered office

Zomerloosstraat 33 box A

8470 Gistel

2.060.503.692

Zomerloosstraat 33/A

8470 Gistel

Active since 25 January 1993

2.229.208.369

Stationsstraat 79

8470 Gistel

Active since 1 February 2014

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0449.135.041
VAT number: BE 0449.135.041
Registered office: Zomerloosstraat 33 bus A, 8470 Gistel
Names & denominations: LITHI - PHARMA
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 6 January 1993
Peppol: Active · Active since 24 Nov 2023
Activities · NACE: Activiteiten van fitnesscentra

View on CBE Public ↗ Annual accounts (NBB) ↗

LITHI - PHARMA

Warning lights

Financials

What happened to LITHI - PHARMA?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions